Healthcare ❯Pharmaceuticals

Alzheimer's Disease

Drug Development Clinical Trials Drug Approval Drug Comparison Market Projections FDA Decisions Treatment Cost Drug Effectiveness Aduhelm Drug Approval Process Drug Mechanism Drug Risks FDA Approval Process FDA Approval

FDA Approves Donanemab: A Breakthrough in Early Alzheimer’s Treatment

Eli Lilly's once-monthly infusion shows significant promise in slowing cognitive decline and reducing amyloid plaques.

FDA Panel Recommends Approval of Promising Alzheimer's Drug Donanemab

FDA Delays Approval of Eli Lilly's Alzheimer's Drug Donanemab